Psallas M, Manes C
Diabetic Center, Papageorgiou Teaching Hospital, Thessaloniki, Greece.
Hippokratia. 2012 Apr;16(2):100-5.
Type 2 diabetes mellitus is the most outspreading disease of the western world and it provides cardiovascular disease. During the past decade new drug categories were added to the already existing ones. Perhaps, the most outstanding, as promising, too, are glucagon-like peptide-1(GLP-1) analogues, which pinpointed at the incretin hormone system, targeting mainly at the postprandial hyperglycemia.It seemed that these novel drugs have beneficial effects on ischemic heart, heart failure,blood pressure, even on lipids and body weight in type 2 diabetics, considering them not only as another glucose lowering agent. A lot of recent studies investigate the potential relationship between GLP-1 and its possible cardioprotective and anti-atherogenic effects in type 2 diabetes and the present review discusses these effects of GLP-1.
2型糖尿病是西方世界传播最广的疾病，它会引发心血管疾病。在过去十年里，在已有的药物种类中又增加了新的类别。也许，最突出且同样有前景的是胰高血糖素样肽-1（GLP-1）类似物，它针对肠促胰岛素激素系统，主要针对餐后高血糖。似乎这些新型药物对2型糖尿病患者的缺血性心脏、心力衰竭、血压，甚至对血脂和体重都有有益影响，因此不仅将它们视为另一种降糖药物。最近许多研究探讨了GLP-1与2型糖尿病中其可能的心脏保护和抗动脉粥样硬化作用之间的潜在关系，本综述讨论了GLP-1的这些作用。
